At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response or better and a 71%…
Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations Clinical responses…
– ENERGIZE is the First Study to Demonstrate Efficacy of an Oral Treatment for Non-Transfusion-Dependent Alpha- and Beta-Thalassemia – – Additional…
LAVAL, QC / ACCESSWIRE / June 14, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global diversified pharmaceutical company enriching…
Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few…
$6 million upfront with up to an additional $18 million of aggregate gross proceeds upon the exercise in full of…
Clinical trials for AI Nose-powered Ainos Flora device moves forward with 75 meaningful case results, paving the way for next-gen…
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company, today announced that it entered into…
Partner’s software products and services are utilized by hundreds of life science organizations, including the top 30 biopharmaceutical companiesMINNEAPOLIS, June…
Vivalink's survey reveals strong consumer support for flexible care models, indicating a need for home based care as part of…